Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, announced on Tuesday that it is constructing a new pharmaceutical manufacturing facility in North Carolina's Research Triangle Park.
The company said it will invest over USD470m in this state-of-the-art facility that will produce parenteral (or injectable) products and delivery devices. In addition, Lilly will create more than 400 jobs in highly skilled positions such as scientists, engineers, quality professionals and manufacturing operations.
"Life science companies like Lilly continue to choose North Carolina," said Roy Cooper, Governor of North Carolina. "Our exceptional workforce draws global companies as we continue to grow North Carolina into a worldwide hub for the biotechnology industry."
AnHorn Medicines reports positive results from US Phase I trial of AH-001
ArkBio commences Phase II clinical trial of AK0610
Curasight advances Phase 2 prostate cancer trial with Curium partnership
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
Rx to Go receives ACHC re-accreditation for pharmacy services
Shanton Pharma completes SAP-001 End-of-Phase 2 meeting with US FDA
Fibronostics completes Stone Clinical Laboratories acquisition